| Lenalidomide | US FDA | Mantle Cell Lymphoma | . • Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib | approved | Dec 27, 2005 | openfda |
| Linvoseltamab | EU EMA | Multiple Myeloma | Monotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.conditional | approved | Apr 23, 2025 | ema |
| Lomustine | US FDA | Hodgkin Lymphoma | Hodgkin's Lymphoma Gleostine is indicated as a component of combination chemotherapy for the treatment of patients with Hodgkin's lymphoma whose disease has progressed following initial chemotherapy. | approved | Aug 4, 1976 | openfda |
| Loncastuximab Tesirine | EU EMA | High Grade B-Cell Lymphoma | Zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy.conditional | approved | Dec 20, 2022 | ema |
| Loncastuximab Tesirine | US FDA | High Grade B-Cell Lymphoma | ZYNLONTA is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma. This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ZYNLONTA is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma. ( 1 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1 )accelerated | approved | Apr 23, 2021 | openfda |
| Mechlorethamine | US FDA | Mycosis Fungoides | VALCHLOR is indicated for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy. VALCHLOR is an alkylating drug indicated for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy ( 1 ). | approved | Aug 23, 2013 | openfda |
| Melphalan | US FDA | Multiple Myeloma | Multiple Myeloma-Palliative Treatment IVRA is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. IVRA is an alkylating drug indicated for palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. ( 1 ) | approved | Aug 18, 2023 | openfda |
| Melphalan | US FDA | Multiple Myeloma | Evomela is an alkylating drug indicated for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma. | approved | Mar 10, 2016 | openfda |
| Melphalan | US FDA | Multiple Myeloma | Evomela is an alkylating drug indicated for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma. | approved | Mar 10, 2016 | openfda |
| Melphalan | US FDA | Multiple Myeloma | Melphalan Hydrochloride for Injection is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. | approved | Jun 9, 2009 | openfda |
| Melphalan Flufenamide | EU EMA | Multiple Myeloma | Pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.4). | approved | Aug 17, 2022 | ema |
| Mercaptopurine | EU EMA | Acute Lymphoblastic Leukemia | Xaluprine is indicated for the treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children. | approved | Mar 9, 2012 | ema |
| Mercaptopurine | US FDA | Acute Lymphoblastic Leukemia | MERCAPTOPURINE is a nucleoside metabolic inhibitor indicated for the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen. | approved | Apr 28, 2014 | openfda |
| Mercaptopurine | US FDA | Acute Lymphoblastic Leukemia | 1 INDICATIONS & USAGE Mercaptopurine tablets is a nucleoside metabolic inhibitor indicated for treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen. | approved | Sep 11, 1953 | openfda |
| Methotrexate | EU EMA | Acute Lymphoblastic Leukemia | In rheumatological and dermatological diseases Active rheumatoid arthritis in adult patients. Polyarthritic forms of active, severe juvenile idiopathic arthritis (JIA) in adolescents and children aged 3 years and over when the response to non-steroidal anti-inflammatory drugs (NSAIDs) has been inadequate. Severe, treatment-refractory, disabling psoriasis which does not respond sufficiently to other forms of treatment such as phototherapy, psoralen and ultraviolet A radiation (PUVA) therapy and retinoids, and severe psoriatic arthritis in adult patients. In oncology Maintenance treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children aged 3 years and over. | approved | Mar 29, 2017 | ema |
| Methotrexate | US FDA | Mycosis Fungoides | Treatment of adults with mycosis fungoides | approved | Nov 29, 2022 | openfda |
| Methotrexate | US FDA | Acute Lymphoblastic Leukemia | Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen | approved | Nov 29, 2022 | openfda |
| Methotrexate | US FDA | Non-Hodgkin Lymphoma | Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen | approved | Nov 29, 2022 | openfda |
| Methotrexate | US FDA | Non-Hodgkin Lymphoma | Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen | approved | Nov 29, 2022 | openfda |
| Methotrexate | US FDA | Acute Lymphoblastic Leukemia | Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen | approved | Nov 29, 2022 | openfda |
| Methotrexate | US FDA | Mycosis Fungoides | Treatment of adults with mycosis fungoides | approved | Nov 29, 2022 | openfda |
| Methotrexate | US FDA | Non-Hodgkin Lymphoma | Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen | approved | Nov 29, 2022 | openfda |
| Methotrexate | US FDA | Acute Lymphoblastic Leukemia | Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen | approved | Nov 29, 2022 | openfda |
| Methotrexate | US FDA | Mycosis Fungoides | Treatment of adults with mycosis fungoides | approved | Nov 29, 2022 | openfda |
| Methotrexate | US FDA | Mycosis Fungoides | Treatment of adults with mycosis fungoides | approved | Nov 29, 2022 | openfda |
| Methotrexate | US FDA | Acute Lymphoblastic Leukemia | Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen | approved | Nov 29, 2022 | openfda |
| Methotrexate | US FDA | Non-Hodgkin Lymphoma | Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen | approved | Nov 29, 2022 | openfda |
| Methotrexate | US FDA | Acute Lymphoblastic Leukemia | Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as a component of a combination chemotherapy maintenance regimen | approved | Apr 25, 2017 | openfda |
| Methotrexate | US FDA | Acute Lymphoblastic Leukemia | Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as a component of a combination chemotherapy maintenance regimen | approved | Apr 25, 2017 | openfda |
| Methotrexate | US FDA | Acute Lymphoblastic Leukemia | The following neoplastic diseases for the: o Treatment of adult and pediatric patients with acute lymphoblastic leukemia as part of a combination chemotherapy regimen. | approved | Aug 10, 1959 | openfda |
| Methotrexate | US FDA | Non-Hodgkin Lymphoma | o Treatment of adult and pediatric patients with non-Hodgkin lymphoma. | approved | Aug 10, 1959 | openfda |
| Methotrexate | US FDA | Meningeal Leukemia | o Prophylaxis and treatment of adult and pediatric patients with meningeal leukemia. | approved | Aug 10, 1959 | openfda |
| Midostaurin | EU EMA | Acute Myeloid Leukemia | Rydapt is indicated: in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Rydapt single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive (see section 4.2); as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM AHN), or mast cell leukaemia (MCL). | approved | Sep 18, 2017 | ema |
| Midostaurin | US FDA | Acute Myeloid Leukemia | Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. | approved | Apr 28, 2017 | openfda |
| Midostaurin | US FDA | Acute Myeloid Leukemia | Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. | approved | Apr 28, 2017 | openfda |
| Mosunetuzumab | EU EMA | Follicular Lymphoma | Lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies.conditional | approved | Jun 3, 2022 | ema |
| Mosunetuzumab | US FDA | Follicular Lymphoma | LUNSUMIO is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).accelerated | approved | Dec 22, 2022 | openfda |
| Moxetumomab Pasudotox | EU EMA | Hairy Cell Leukemia | Lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (HCL) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (PNA). | withdrawn | Feb 8, 2021 | ema |
| Nilotinib | EU EMA | Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive | Nilotinib Accord is indicated for the treatment of: - adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase, - adult patients with chronic phase and accelerated phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. Efficacy data in patients with CML in blast crisis are not available, - paediatric patients with chronic phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. | approved | Aug 22, 2024 | ema |
| Nilotinib | EU EMA | Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive | Tasigna is indicated for the treatment of: adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase, paediatric patients with Philadelphia chromosome positive CML in chronic phase with resistance or intolerance to prior therapy including imatinib. Tasigna is indicated for the treatment of: adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase, adult patients with chronic phase and accelerated phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. Efficacy data in patients with CML in blast crisis are not available, paediatric patients with chronic phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. | approved | Nov 19, 2007 | ema |
| Nilotinib | US FDA | Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 Positive | Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib. | approved | May 29, 2026 | openfda |
| Nilotinib | US FDA | Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 Positive | Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib. | approved | Feb 19, 2025 | openfda |
| Nilotinib | US FDA | Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 Positive | Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib. | approved | Nov 7, 2024 | openfda |
| Nilotinib | US FDA | Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 Positive | Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib. | approved | Oct 29, 2007 | openfda |
| Nilotinib | US FDA | Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 Positive | Pediatric patients greater than or equal to 1 year of age with Ph+ CML-CP and CML-AP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy. | approved | Oct 29, 2007 | openfda |
| Nivolumab | US FDA | Classic Hodgkin Lymphoma | adult patients with classical Hodgkin lymphoma that has relapsed or progressed after: | approved | Dec 22, 2014 | openfda |
| Nivolumab | US FDA | Classic Hodgkin Lymphoma | Classical Hodgkin Lymphoma (cHL) • adult and pediatric (12 years and older) patients with previously untreated, Stage III or IV classical Hodgkin lymphoma in combination with doxorubicin, vinblastine, and dacarbazine (AVD). | approved | Dec 22, 2014 | openfda |
| Obecabtagene Autoleucel | EU EMA | B Acute Lymphoblastic Leukemia | Aucatzyl is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory (r/r) B cell precursor acute lymphoblastic leukaemia (B ALL).conditional | approved | Jul 17, 2025 | ema |
| Obinutuzumab | US FDA | Follicular Lymphoma | in combination with bendamustine followed by GAZYVA monotherapy, for the treatment of patients with follicular lymphoma (FL)who relapsed after, or are refractory to, a rituximab-containing regimen. | approved | Nov 1, 2013 | openfda |
| Obinutuzumab | US FDA | Chronic Lymphocytic Leukemia | in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL). | approved | Nov 1, 2013 | openfda |